In tumor immunotherapy, the potency of dendritic cell (DC)‐EVs and C‐EVs, as components of a cell‐free tumor vaccine, has been receiving increasing attention.89, 90 Initially, DC‐EVs were found to play a role in antigen presentation by triggering a T cell‐dependent immune response, thus annihilating tumors.89 DC‐EVs were subsequently found to promote the activation of natural killer cells91 and B cells.92 Additionally, C‐EVs, after internalization by DCs, can further lead to the rejection of tumors via CD8+ T‐cell‐dependent antitumor effects.90 The gene discussed is CD8A; the disease is neoplasm.